Skip to main content

Table 2 Treatment outcomes and associated factors among adult persons with complete SVR data receiving SOF-based regimens within the national hepatitis C elimination program, April 28, 2015 – October 31, 2018

From: Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia

 Total NAchieved SVRBivariate analysisMultivariate analysis
N%RR95% CIp valueRR95% CIp value
Age category
 18–451635144088.071     
 46–602838225979.600.900.88–0.93<0.0001   
 60+60647177.720.880.84–0.92<0.0001   
Gender
 Female69856080.231     
 Male4381361082.401.030.99–1.070.18   
HCV Genotype
 11724119869.491  1  
 2104785281.381.171.12–1.22<0.00011.101.05–1.15<0.0001
 32305211791.841.321.28–1.37<0.00011.141.11–1.18<0.0001
 433100.00
HCV RNA categories, n (%)
 < 800,000 IU/mL2922240882.411     
 ≥ 800,000 IU/mL2145175481.770.990.97–1.020.56   
FIB-4 Tests
 < 1.4520017788.501  1  
 1.45–3.251763157389.221.010.96–1.060.761.000.93–1.070.95
 > 3.251546116675.420.850.80–0.90<0.00010.950.87–1.020.17
Metavir score
 < F42021176187.141  1  
 F42783216177.650.890.87–0.97<0.00010.950.93–0.980.0001
Co-infections
 HBsAg-4777389781.581     
 HBsAg+1088982.411.010.92–1.100.82   
Treatment regimen
 IFN/SOF/RBV (12 wk)2646241691.311  1  
 SOF/RBV (12 wk)36427675.820.830.78–0.88<0.00010.850.81–0.91<0.0001
 SOF/RBV (20 wk)39530276.460.840.79–0.89<0.00010.860.82–0.92<0.0001
 SOF/RBV (24 wk)141897969.040.760.73–0.78<0.00010.880.85–0.91<0.0001
 SOF/RBV (48 wk)25619776.950.840.79–0.90<0.00010.920.87–0.980.005
City of treatment site
 Tbilisi3800312782.291  1  
 Kutaisi36227275.140.910.86–0.970.0040.960.92–1.010.10
 Batumi50143586.831.061.02–1.100.0051.010.97–1.050.60
 Zugdidi32825878.660.960.90–1.010.130.960.92–1.000.07
 Gori424095.241.161.08–1.24<0.00011.010.87–1.170.91
 Rustavi403280.000.970.83–1.140.720.950.80–1.130.55
 Lanchkhuti44100.00
 Gurjaani22100.00
  1. SOF Sofosbuvir, RBV Ribavirin, IFN Interferon, CI Confidence interval, RR Risk ratio, SVR Sustained virologic response